Technical Analysis for ACHL - Achilles Therapeutics plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| 20 DMA Support | Bullish | 1.90% | |
| Gapped Down | Weakness | 1.90% | |
| New Uptrend | Bullish | 1.90% | |
| Inside Day | Range Contraction | 1.90% | |
| Upper Bollinger Band Walk | Strength | 1.90% | |
| Upper Bollinger Band Touch | Strength | 1.90% | |
| Gapped Down | Weakness | 1.90% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 18 hours ago |
| 10 DMA Support | about 18 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
| Down 2 % | about 18 hours ago |
| Down 1% | about 18 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Antineoplastic Drugs Melanoma Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical Triple Negative Breast Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Antineoplastic Drugs Melanoma Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical Triple Negative Breast Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.76 |
| 52 Week Low | 0.63 |
| Average Volume | 847,534 |
| 200-Day Moving Average | 0.94 |
| 50-Day Moving Average | 0.98 |
| 20-Day Moving Average | 1.03 |
| 10-Day Moving Average | 1.05 |
| Average True Range | 0.04 |
| RSI (14) | 64.41 |
| ADX | 24.37 |
| +DI | 25.12 |
| -DI | 15.54 |
| Chandelier Exit (Long, 3 ATRs) | 0.99 |
| Chandelier Exit (Short, 3 ATRs) | 1.07 |
| Upper Bollinger Bands | 1.08 |
| Lower Bollinger Band | 0.97 |
| Percent B (%b) | 0.89 |
| BandWidth | 10.53 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.0005 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.15 | ||||
| Resistance 3 (R3) | 1.14 | 1.10 | 1.13 | ||
| Resistance 2 (R2) | 1.10 | 1.08 | 1.11 | 1.13 | |
| Resistance 1 (R1) | 1.09 | 1.07 | 1.10 | 1.10 | 1.12 |
| Pivot Point | 1.05 | 1.05 | 1.06 | 1.06 | 1.05 |
| Support 1 (S1) | 1.04 | 1.03 | 1.05 | 1.05 | 1.02 |
| Support 2 (S2) | 1.00 | 1.02 | 1.01 | 1.01 | |
| Support 3 (S3) | 0.99 | 1.00 | 1.01 | ||
| Support 4 (S4) | 1.00 |
